Your session is about to expire
← Back to Search
NK Cell Therapy + Chemotherapy for Advanced Kidney, Lung, or Bone Cancer
Study Summary
This trial will test a therapy of donated NK cells & chemo for advanced kidney, lung, or bone cancer patients to find the best dose.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I've had targeted radiation before chemo, but still have untreated cancer areas.I can do all my daily activities without help.My cancer shows high CD70 levels in tests.It has been over 3 months since my last cell therapy for cancer.I stopped my last strong cancer treatment at least 2 weeks ago and any targeted therapy 3 days before starting the new treatment.I do not have any serious health conditions that could make the treatment unsafe for me.My kidney, liver, heart, lungs, blood, and clotting functions are all within normal ranges.I am between 18 and 80 years old.I am not pregnant and can become pregnant.I have active hepatitis B or C, or HIV with a detectable viral load.I weigh at least 40 kg.I have symptoms or uncontrolled issues in my brain or spinal cord.I am currently fighting an infection that needs IV drugs or isn't getting better with treatment.I haven't had an active autoimmune disease, except for mild psoriasis or stable thyroid issues, in the last year.I have been diagnosed with amyloidosis or POEMS syndrome.I have an active neurological disorder.I have severe side effects from past cancer treatment.I haven't had any cancer except for certain skin cancers or cervical cancer in the last 2 years.My condition is either Renal Cell Carcinoma, Mesothelioma, or Osteosarcoma.
- Group 1: Chemotherapy and NK Cell Infusion
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are individuals younger than 80 years of age permissible for this experiment?
"As detailed in the eligibility criteria, the patient population for this clinical trial consists of those aged 18 to 80. For patients under 18 and over 65 there are 177 trials and 2,649 trials respectively available."
Are patients able to participate in this research at present?
"As per information on clinicaltrials.gov, this study began recruitment on March 1st 2023 and ceased accepting patients as of January 27th 2023. Although this trial is not accepting applicants currently, there are 2,735 other studies open for enrollment at the moment."
What eligibility criteria must potential participants satisfy to take part in the medical research?
"This medical trial is presently looking for 50 individuals aged between 18 and 80 that are experiencing kidney cancer. Moreover, these patients must meet the following conditions: have given their informed consent to long-term follow up on protocol PA17-0483, possess advanced clear cell renal carcinoma, osteosarcoma or mesothelioma with CD70 expression of 10% in pre-enrollment tumor sample via immunohistochemistry or flow cytometry; fulfil disease specific criteria (see below); be at least 2 weeks from last chemotherapy before lymphodepleting chemotherapy procedure; haven't had any cell therapy for malignancy within"
Share this study with friends
Copy Link
Messenger